Alterity Therapeutics Ltd.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David A. Stamler
- Full Time Employees
- 11
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 500 Collins Street Melbourne VIC Australia 3000
- IPO Date
- Mar 28, 2000
- Website
- alteritytx.com
- Similar Companies
- Business
- Alterity Therapeutics Limited (ASX:ATH; NASDAQ:ATHE), a clinical-stage biotechnology company founded in 1997 and headquartered in Melbourne, Australia, with operations in the United States, develops disease-modifying therapies targeting neurodegenerative diseases including multiple system atrophy, Parkinson's disease, Alzheimer's disease, and Huntington's disease; its lead product candidate ATH434, an oral small molecule that inhibits alpha-synuclein aggregation and redistributes excess brain iron to reduce oxidative stress, has completed Phase 2 clinical trials in early-stage multiple system atrophy demonstrating positive topline results with robust clinical efficacy including a 48% treatment effect, FDA Fast Track and Orphan Drug designations, and ongoing open-label extension studies; the company also advances a preclinical pipeline of next-generation small molecules addressing protein misfolding pathology in Parkinsonian disorders. Alterity Therapeutics conducts global clinical trials across Australia, the United States, the United Kingdom, Italy, France, and Austria, and supports natural history studies like bioMUSE to validate imaging and biomarker endpoints for disease progression. In September 2025, the company raised A$20 million through a strategic placement to institutional investors led by a major international healthcare fund to advance ATH434's regulatory strategy with the FDA and pursue partnerships; recent milestones include FDA Fast Track Designation for ATH434 in May 2025, completion of last patient visits in Phase 2 trials ATH434-201 and ATH434-202 in December 2024 and March 2025 respectively, positive Phase 2 data announcements in January 2025, multiple data presentations at medical congresses including the International MSA Congress and American Academy of Neurology in 2025, appointment of Abby Macnish Niven as Chief Financial Officer in September 2024, and new publications on ATH434's neuroprotective mechanisms and composition-of-matter patents in Europe and the United States.
Company News
Alterity Therapeutics to Present at the Canaccord Genuity Drug and Device Conference
Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson's Disease and Movement Disorders
Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) Stock Has Average Price Target of $10.00
Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
Alterity Therapeutics to Present at the 46th Annual Canaccord Genuity Growth Conference
Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder
Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy
Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy
Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
Alterity Therapeutics Limited (ATHE) Discusses Phase II Data and Development Strategy for ATH434 in Multiple System Atrophy Transcript
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
Head to Head Contrast: NovoCure (NASDAQ:NVCR) versus Alterity Therapeutics (NASDAQ:ATHE)